We found that high GLS, FBLL1, and MEX3B expressions were associated with poor overall survival, as was the hypomethylation of GLS and MEX3B. The theoretical basis behind the development of metabolic therapies is that altered glutamine metabolism is a hallmark of cancer progression. This evidence concerns the gene MEX3B and cancer.